Clinical Adoption Solea's FDA-cleared all-tissue laser delivers anesthesia-free, blood-free, and suture-free procedures, offering a clear efficiency and patient experience advantage that resonates with general, pediatric, and anxious patients. Target high-volume practices and DSOs with ROI-based proposals, pilots, and bundled training to drive rapid adoption and case growth.

Perioguide Expansion The launch of Solea Perioguide opens an entry point into moderate to severe periodontitis treatment, enabling minimally invasive therapies. Focus on periodontists and general dentists performing perio, offer bundled training and equipment upgrades, and collaborate with dental schools to validate and showcase Perioguide in curriculum and clinical trials.

Academic Partnerships Ongoing collaboration with The Ohio State University College of Dentistry and involvement of Harvard School of Dental Medicine bolster credibility and provide channels for clinical training centers and teaching clinics. Leverage these ties to secure large institutional pilots, education contracts, and preferred vendor status in university networks.

Go To Market Recent addition of a Chief Commercial Officer signals a renewed focus on scalable sales, pricing, and channel strategies. Prioritize distributor partnerships, mid-market DSOs, and multi-location practices with a clear sales playbook, compelling case studies, and local training to accelerate pipeline and revenue growth.

Market Positioning Private status with mid-market revenue and strategic board appointments suggests opportunities to fund rapid expansion and manufacturing scale. Position Solea as a differentiated platform with horizontal applications across preventive and restorative dentistry, supported by financing options and partnerships with financial leaders to ease clinic acquisitions and upsell of Perioguide and Protect modules.